TB-01CD200 CHECKPOINT BLOCKADE PLAYS AN IMPORTANT ROLE IN CNS TUMOR IMMUNOEDITING
نویسندگان
چکیده
منابع مشابه
ASXL1 plays an important role in erythropoiesis
ASXL1 mutations are found in a spectrum of myeloid malignancies with poor prognosis. Recently, we reported that Asxl1(+/-) mice develop myelodysplastic syndrome (MDS) or MDS and myeloproliferative neoplasms (MPN) overlapping diseases (MDS/MPN). Although defective erythroid maturation and anemia are associated with the prognosis of patients with MDS or MDS/MPN, the role of ASXL1 in erythropoiesi...
متن کاملERK1/2 Signaling Plays an Important Role in Topoisomerase II Poison-Induced G2/M Checkpoint Activation
Topo II poisons, which target topoisomerase II (topo II) to generate enzyme mediated DNA damage, have been commonly used for anti-cancer treatment. While clinical evidence demonstrate a capability of topo II poisons in inducing apoptosis in cancer cells, accumulating evidence also show that topo II poison treatment frequently results in cell cycle arrest in cancer cells, which was associated wi...
متن کاملCheckpoint protein Rad9 plays an important role in nucleotide excision repair.
Rad9, an evolutionarily conserved checkpoint gene with multiple functions for preserving genomic integrity, has been shown to play important roles in homologous recombination repair, base excision repair and mismatch repair. However, whether Rad9 has an impact on nucleotide excision repair remains unknown. Here we demonstrated that Rad9 was involved in nucleotide excision repair and loss of Rad...
متن کاملDysregulation of JAM-A plays an important role in human tumor progression.
Junctional adhesion molecule A (JAM-A) is a transmembrane protein that belongs to the immunoglobulin (Ig) superfamily. Evidence determines that JAM-A plays a role in numerous cellular processes, including tight junction assembly, leukocyte migration, platelet activation, angiogenesis and virus binding. Recent research suggests that JAM-A is dysregulated in various cancers and is vital for tumor...
متن کاملLIGHTing tumor up for checkpoint blockade
Immune checkpoint blockade, as a breakthrough in cancer therapy with anti-PD-L1, anti-PD-1, and anti-CTLA4, has demonstrated impressive therapeutic effects in multiple clinical trials. However, only a small minority of patients respond to such therapies [1]. Higher tumor infiltrating lymphocytes (TILs) and PD-L1 expression in tumors have been found to correlate with better prognoses [2, 3]. How...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2016
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/now084.01